✦ LIBER ✦

Final 5-year results of Z-FAST trial : Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole

✍ Scribed by Adam M. Brufsky; W. Graydon Harker; J. Thaddeus Beck; Linda Bosserman; Charles Vogel; Christopher Seidler; Lixian Jin; Ghulam Warsi; Eliza Argonza-Aviles; John Hohneker; Solveig G. Ericson; Edith A. Perez

Book ID: 102806317
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 1023 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26313

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Zoledronic Acid Effectively Prevents Aro

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

✍ Adam M. Brufsky; Linda D. Bosserman; Richard R. Caradonna; Barbara B. Haley; C. 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 151 KB

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the

0132 The effect of zoledronic acid in po

0132 The effect of zoledronic acid in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO-FAST trials

✍ A. Frassoldati; A. Brufsky; N. Bundred; R. Lambert-Falls; P. Hadji; N. Schenk; O 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Zoledronic acid in the prevention of can

Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study)

✍ N. Bundred; Campbell; R. Coleman; R. DeBoer; H. Edidtmann; A. Frassolati; A. Llo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 126 KB

2008 POSTER The E-ZO-FAST trial: Zoledro

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

✍ N. Schenk; A. Lombart; A. Frassoladti; P. Neven; G. Jerusalem; I. Deleu; J. Mebi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Zoledronic acid prevents bone mineral de

Zoledronic acid prevents bone mineral density loss in premenopausal women receiving adjuvant treatment for hormone receptor-positive breast cancer: Preliminary results of a randomized, multicenter trial of zoledronic acid in patients receiving anastrozole or tamoxifen in combination with goserelin

✍ H. Hausmaninger 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 184 KB